Kelly Scaggs Campen
Examiner (ID: 2758, Phone: (571)272-6740 , Office: P/3691 )
Most Active Art Unit | 3691 |
Art Unit(s) | 3624, 2165, 2164, 3312, 3738, 3691 |
Total Applications | 1052 |
Issued Applications | 501 |
Pending Applications | 228 |
Abandoned Applications | 322 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 13870781
[patent_doc_number] => 20190031731
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-31
[patent_title] => BIGLYCAN VARIANT POLYPEPTIDES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/156578
[patent_app_country] => US
[patent_app_date] => 2018-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15242
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16156578
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/156578 | BIGLYCAN VARIANT POLYPEPTIDES AND METHODS OF USE | Oct 9, 2018 | Abandoned |
Array
(
[id] => 17022349
[patent_doc_number] => 20210246220
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => Anti-BCMA single-chain antibody scFv and preparation method and application thereof
[patent_app_type] => utility
[patent_app_number] => 17/283976
[patent_app_country] => US
[patent_app_date] => 2018-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6671
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 370
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283976
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/283976 | Anti-BCMA single-chain antibody scFv and preparation method and application thereof | Oct 9, 2018 | Pending |
Array
(
[id] => 17029747
[patent_doc_number] => 11091552
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-17
[patent_title] => Specific binding molecule directed against galectin-3 protein
[patent_app_type] => utility
[patent_app_number] => 16/753671
[patent_app_country] => US
[patent_app_date] => 2018-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 8
[patent_no_of_words] => 14087
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16753671
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/753671 | Specific binding molecule directed against galectin-3 protein | Oct 4, 2018 | Issued |
Array
(
[id] => 15666447
[patent_doc_number] => 10597441
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-24
[patent_title] => Humanized antibodies that recognize alpha-synuclein
[patent_app_type] => utility
[patent_app_number] => 16/144923
[patent_app_country] => US
[patent_app_date] => 2018-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 14
[patent_no_of_words] => 16602
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16144923
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/144923 | Humanized antibodies that recognize alpha-synuclein | Sep 26, 2018 | Issued |
Array
(
[id] => 14098999
[patent_doc_number] => 20190091175
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-28
[patent_title] => METHOD OF REDUCTION MEDICATION IN TREATING DRAVET SYNDROME
[patent_app_type] => utility
[patent_app_number] => 16/139701
[patent_app_country] => US
[patent_app_date] => 2018-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21300
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16139701
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/139701 | METHOD OF REDUCTION MEDICATION IN TREATING DRAVET SYNDROME | Sep 23, 2018 | Abandoned |
Array
(
[id] => 16343889
[patent_doc_number] => 20200308539
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => AFFINITY-TAGGED PHOTOSWITCHES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/649525
[patent_app_country] => US
[patent_app_date] => 2018-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26315
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -53
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649525
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/649525 | AFFINITY-TAGGED PHOTOSWITCHES AND METHODS OF USE THEREOF | Sep 20, 2018 | Pending |
Array
(
[id] => 14132379
[patent_doc_number] => 20190100579
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-04
[patent_title] => ANTI-PACAP ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/136490
[patent_app_country] => US
[patent_app_date] => 2018-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7857
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16136490
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/136490 | Anti-PACAP antibody | Sep 19, 2018 | Issued |
Array
(
[id] => 14018995
[patent_doc_number] => 20190071491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-07
[patent_title] => ANTI-TRANSTHYRETIN ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/129618
[patent_app_country] => US
[patent_app_date] => 2018-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37732
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129618
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/129618 | Anti-transthyretin antibodies | Sep 11, 2018 | Issued |
Array
(
[id] => 14018971
[patent_doc_number] => 20190071479
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-07
[patent_title] => PURIFIED BIGLYCAN VARIANTS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/124062
[patent_app_country] => US
[patent_app_date] => 2018-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15182
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16124062
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/124062 | PURIFIED BIGLYCAN VARIANTS AND METHODS OF USE THEREOF | Sep 5, 2018 | Abandoned |
Array
(
[id] => 17490468
[patent_doc_number] => 11279757
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-22
[patent_title] => Antibodies useful in cancer diagnosis
[patent_app_type] => utility
[patent_app_number] => 16/641160
[patent_app_country] => US
[patent_app_date] => 2018-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 25593
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 486
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16641160
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/641160 | Antibodies useful in cancer diagnosis | Sep 4, 2018 | Issued |
Array
(
[id] => 14504475
[patent_doc_number] => 20190195892
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-27
[patent_title] => METHOD OF DISTINGUISHING BETWEEN DIFFERENT NEURODEGENERATIVE DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/121481
[patent_app_country] => US
[patent_app_date] => 2018-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20847
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16121481
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/121481 | METHOD OF DISTINGUISHING BETWEEN DIFFERENT NEURODEGENERATIVE DISEASES | Sep 3, 2018 | Abandoned |
Array
(
[id] => 16807843
[patent_doc_number] => 20210130396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => METHOD FOR PURIFYING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/640073
[patent_app_country] => US
[patent_app_date] => 2018-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9819
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16640073
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/640073 | METHOD FOR PURIFYING PROTEINS | Aug 28, 2018 | Abandoned |
Array
(
[id] => 16452595
[patent_doc_number] => 20200362021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => ANTI-APELIN ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/639808
[patent_app_country] => US
[patent_app_date] => 2018-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24316
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639808
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/639808 | Anti-apelin antibodies and uses thereof | Aug 20, 2018 | Issued |
Array
(
[id] => 13986515
[patent_doc_number] => 20190062415
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-28
[patent_title] => ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN
[patent_app_type] => utility
[patent_app_number] => 16/107949
[patent_app_country] => US
[patent_app_date] => 2018-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17560
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16107949
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/107949 | Antibodies recognizing alpha-synuclein | Aug 20, 2018 | Issued |
Array
(
[id] => 15493249
[patent_doc_number] => 20200046813
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-13
[patent_title] => Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals
[patent_app_type] => utility
[patent_app_number] => 16/102134
[patent_app_country] => US
[patent_app_date] => 2018-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31953
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16102134
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/102134 | Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals | Aug 12, 2018 | Abandoned |
Array
(
[id] => 17044940
[patent_doc_number] => 11098108
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-24
[patent_title] => Antibody binding active alpha-synuclein
[patent_app_type] => utility
[patent_app_number] => 16/635943
[patent_app_country] => US
[patent_app_date] => 2018-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 27
[patent_no_of_words] => 19942
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635943
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/635943 | Antibody binding active alpha-synuclein | Aug 1, 2018 | Issued |
Array
(
[id] => 13990061
[patent_doc_number] => 20190064188
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-28
[patent_title] => MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY
[patent_app_type] => utility
[patent_app_number] => 16/052512
[patent_app_country] => US
[patent_app_date] => 2018-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24205
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16052512
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/052512 | MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY | Jul 31, 2018 | Abandoned |
Array
(
[id] => 13586515
[patent_doc_number] => 20180344806
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals
[patent_app_type] => utility
[patent_app_number] => 16/046448
[patent_app_country] => US
[patent_app_date] => 2018-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29664
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046448
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/046448 | Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals | Jul 25, 2018 | Abandoned |
Array
(
[id] => 13549347
[patent_doc_number] => 20180326221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-15
[patent_title] => SYSTEM FOR OPTICAL STIMULATION OF TARGET CELLS
[patent_app_type] => utility
[patent_app_number] => 16/041647
[patent_app_country] => US
[patent_app_date] => 2018-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18107
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -56
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16041647
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/041647 | SYSTEM FOR OPTICAL STIMULATION OF TARGET CELLS | Jul 19, 2018 | Abandoned |
Array
(
[id] => 18505701
[patent_doc_number] => 11703511
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-18
[patent_title] => Anti-isoAsp7 amyloid b (Ab) antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/632289
[patent_app_country] => US
[patent_app_date] => 2018-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 20
[patent_no_of_words] => 18044
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16632289
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/632289 | Anti-isoAsp7 amyloid b (Ab) antibodies and uses thereof | Jul 16, 2018 | Issued |